聚乙二醇化
生物制药
聚乙二醇
药理学
PEG比率
小分子
药代动力学
药品
医学
寡核苷酸
化学
生物化学
生物技术
生物
业务
DNA
财务
作者
Jung Seok Kang,Patrick P. DeLuca,Kang Choon Lee
标识
DOI:10.1517/14728210902907847
摘要
PEGylation is a pharmaceutical technology that involves the covalent attachment of polyethylene glycol (PEG) to a drug to improve its pharmacokinetic, pharmacodynamic, and immunological profiles, and thus, enhance its therapeutic effect. Currently, PEGylation is used to modify proteins, peptides, oligonucleotides, antibody fragments, and small organic molecules. Research groups are striving to improve the consistencies of PEGylated drugs and to PEGylate commercialized proteins and small organic molecules. Furthermore, the PEGylations of novel medications, like oligonucleotides and antibody fragments, are being pursued to improve their bioavailabilities. This active research in the PEGylation field and the continued growth of the biopharmaceutical market predicts that PEGylated drugs have a bright future.
科研通智能强力驱动
Strongly Powered by AbleSci AI